Today the European Social Insurance Platform (ESIP) and the Medicine Evaluation Committee (MEDEV) publish a comprehensive set of recommendations on the proposals to reform of the EU general pharmaceutical legislation, presented by the European Commission in April 2023.
The conundrum of high pharmaceutical prices often coupled with incomplete evidence at time of marketing authorisation affect national pricing and reimbursement decisions and consequently access to affordable treatment. In order to preserve the sustainability of European healthcare systems, experts from public bodies responsible for health technology assessment (HTA), pricing and reimbursement (P&R) and public health insurers present a joint set of proposals to improve the EU pharmaceutical legislation, towards producing solid evidence for informed decision-making across the product lifecycle and promoting competition for affordable access to treatment. Our proposals in a nutshell: Find more in our ESIP & MEDEV position paper on the revision of the EU pharmaceutical legislation. Main page picture - Source: EC - Audiovisual Service, European Union, 2023